Haoran Xia

870 total citations · 1 hit paper
30 papers, 337 citations indexed

About

Haoran Xia is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Haoran Xia has authored 30 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 10 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Haoran Xia's work include Cancer Immunotherapy and Biomarkers (7 papers), Prostate Cancer Treatment and Research (7 papers) and Ferroptosis and cancer prognosis (6 papers). Haoran Xia is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Prostate Cancer Treatment and Research (7 papers) and Ferroptosis and cancer prognosis (6 papers). Haoran Xia collaborates with scholars based in China, Taiwan and United Kingdom. Haoran Xia's co-authors include Gening Jiang, Peng Zhang, Fenghuan Sun, Ming Liu, Liangdong Sun, Pengyu Fan, Ya Han, Dianke Li, Yan Chen and Xinsheng Zhu and has published in prestigious journals such as Environmental Science & Technology, Annals of Oncology and Gene.

In The Last Decade

Haoran Xia

26 papers receiving 332 citations

Hit Papers

Tumor microenvironment remodeling after neoadjuvant immun... 2023 2026 2024 2025 2023 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing
    2023 152 citations Junjie Hu, Lele Zhang et al. Genome Medicine profile →

Peers

Haoran Xia
Fenghuan Sun China
Shaochuan Liu China
Miao Huang China
Daiyuan Ma China
Sofia Westbom-Fremer Sweden
Brian Schillinger United States
Jiaqi Su China
Christoforos Vaxevanis Germany
Sarah Bourass France
Maciej Głogowski Poland
Fenghuan Sun China
Haoran Xia
Citations per year, relative to Haoran Xia Haoran Xia (= 1×) peers Fenghuan Sun

Countries citing papers authored by Haoran Xia

Since Specialization
Citations

This map shows the geographic impact of Haoran Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haoran Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haoran Xia more than expected).

Fields of papers citing papers by Haoran Xia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haoran Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haoran Xia. The network helps show where Haoran Xia may publish in the future.

Co-authorship network of co-authors of Haoran Xia

This figure shows the co-authorship network connecting the top 25 collaborators of Haoran Xia. A scholar is included among the top collaborators of Haoran Xia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haoran Xia. Haoran Xia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bian, Dongliang, Wentian Zhang, Fenghuan Sun, et al.. (2025). Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial. BMC Medicine. 23(1). 429–429. 1 indexed citations
2.
3.
Xia, Haoran, et al.. (2025). TMSB10 drives prostate cancer aggressiveness via immune microenvironment regulation. Molecular Medicine. 31(1). 160–160. 1 indexed citations
4.
Chu, Qiao, Fenghuan Sun, Xinsheng Zhu, et al.. (2025). Longitudinal relationship between posttraumatic growth and distress in lung cancer patients during neoadjuvant immunotherapy. International Journal of Clinical and Health Psychology. 25(1). 100549–100549.
5.
Wang, Haoran, Zhengtong Lv, Haoran Xia, et al.. (2023). Cuproptosis-related long noncoding RNAs predicts overall survival and reveal immune microenvironment of bladder cancer. Heliyon. 9(12). e21153–e21153. 3 indexed citations
6.
Hu, Junjie, Lele Zhang, Haoran Xia, et al.. (2023). Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Medicine. 15(1). 14–14. 152 indexed citations breakdown →
7.
Guo, Xiaoxiao, et al.. (2023). Real-world progression in the survival of de novo Metastatic prostate cancer over the past decade. Urologic Oncology Seminars and Original Investigations. 42(3). 68.e1–68.e9. 2 indexed citations
8.
9.
Liu, Jingchao, Zhipeng Zhang, Wei Zhang, et al.. (2022). Ferroptosis Mediation Patterns Reveal Novel Tool to Implicate Immunotherapy and Multi-Omics Characteristics in Bladder Cancer. Frontiers in Cell and Developmental Biology. 10. 791630–791630. 9 indexed citations
10.
Xia, Haoran, et al.. (2022). The Value of Lymph Node Dissection in Patients With Node-Positive Upper Urinary Tract Urothelial Cancer: A Retrospective Cohort Study. Frontiers in Oncology. 12. 889144–889144. 2 indexed citations
11.
Liu, Jingchao, Wei Zhang, Jiawen Wang, et al.. (2022). Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer. Journal of Cancer Research and Clinical Oncology. 149(5). 1969–1983. 5 indexed citations
12.
Zhang, Peng, Jie Dai, Fenghuan Sun, et al.. (2022). Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery. 114(3). 949–958. 41 indexed citations
13.
14.
15.
Guo, Xiaoxiao, Haoran Xia, Huimin Hou, Ming Liu, & Jianye Wang. (2021). Comparison of Oncological Outcomes Between Radical Prostatectomy and Radiotherapy by Type of Radiotherapy in Elderly Prostate Cancer Patients. Frontiers in Oncology. 11. 708373–708373. 5 indexed citations
16.
Yang, Jie, Haoran Xia, Fenghuan Sun, Peng Zhang, & Gening Jiang. (2021). Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report. Annals of Translational Medicine. 9(8). 724–724.
17.
Zhang, Zhichao, Shuai Yu, Jing Li, et al.. (2021). Epigenetic modifications potentially controlling the allelic expression of imprinted genes in sunflower endosperm. BMC Plant Biology. 21(1). 570–570. 2 indexed citations
18.
Liu, Jingchao, Meng Wu, Wei Zhang, et al.. (2021). Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer. Frontiers in Medicine. 8. 757432–757432. 7 indexed citations
19.
20.
Xia, Haoran, et al.. (2019). Effect of polymorphism on IL1A to cancer susceptibility: Evidence based on 34,016 subjects. Artificial Cells Nanomedicine and Biotechnology. 47(1). 3138–3152. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fenghuan Sun Breakdown of academic impact, for papers by Shaochuan Liu Breakdown of academic impact, for papers by Miao Huang Breakdown of academic impact, for papers by Daiyuan Ma Breakdown of academic impact, for papers by Sofia Westbom-Fremer Breakdown of academic impact, for papers by Brian Schillinger Breakdown of academic impact, for papers by Jiaqi Su Breakdown of academic impact, for papers by Christoforos Vaxevanis Breakdown of academic impact, for papers by Sarah Bourass Breakdown of academic impact, for papers by Maciej Głogowski
Rankless by CCL
2026